50'O control levels (ICi.) of 20-50p There was dose dependent inhibition of colony forming efficiency (CFE) in 3 3 SCLC and 1 1 N-SCLC CL. ICio, of 0.5 -6. (Cuttitta et al.. 1985) and insulin-like growth factor-I (IGF-1) (Macaulay et al.. 1988) . which appear to operate as autocrine grow-th factors. Analogues which block the growth effects of these factors may provide new approaches to therapy.
Substance P (SP) was first isolated in 1931 (Euler & Gaddum. 1931 ). It is a basic 11 amino acid sensory neurotransmitter belonging to the Widely distributed tachykinin family. Tachykinins possess a common C-terminal tripeptide GlyLeu-Met-NH.. The family includes substance K (neurokinin A). neurokinin B. eledoisin. physalaemin, kassinin. uperlein and phyllomedusin. Physalaemin-like peptides are produced by SCLC cell lines (CLs) (Lazarus et al.. 1983) . and have an inhibitory effect on lung cancer cell growth in vitro (Bepler et al.. 1987) .
Tachykinins have a variety of physiological effects including the contraction of smooth muscle, lowering blood pressure and stimulatory effects on spinal or sensory neurons. SP may also have a role in acute inflammation (Matsuda et al.. 1989) . SP analogues abolish the behavioural effects of SP (Lembeck et al.. 1981) . antagonise the effects of bombesin in vivo (Yachnis et al.. 1984) , and have potent local anaesthetic actions (Piercey et al.. 1981; Post et al.. 1985) .
Analogues of SP were found to block the release of amylase from pancreatic acinar cells in vitro, by the competitive inhibition of peptides which interact with the bombesin receptor (Jensen et al., 1984) . They also inhibited the mitogenic stimulation of Swiss 3T3 cells by bombesin. vasopressin and bradykinin (Corps et al., 1985; Woll & Rozengurt. 1988a) . These peptides have no significant sequence homology with SP, and it has been suggested that SP analogues recognise a common domain in the receptors for these neuropeptides, which is not the ligand binding site (Woll & Rozengurt. 1988a ). Woll and Rozengurt (1988b) (Woll & Rozengurt. 1988b : Bepler et al.. 1989 Woll & Rozengurt. 1990 ). We have studied the effect of D-Phe'SP on grow-th on ten human tumour cell lines and normal human cells. Gronsth assays All assays were performed in RPMI-1640 medium supplemented with 5Oo FCS unless stated otherwise.
Materials and methods

Cell lines
DNA synthesis DNA synthesis was measured by 'H-thvimidine incorporation (Rozengurt & Heppel. 1975 (Figure 3 ). In contrast 50 gM DPhe5SP had no effect on the cell number of confluent cultures of normal human skin fibroblasts, however 100 gm caused inhibition to 83 ± 2% control (P<0.01) (Figure 3 ).
Effect of short term exposure to 100 gM.W analogue HC12 viable cell number dropped on exposure to 100 1M D-Phe5SP for 1-4 h. After I h the treated cell number fell to 55 ± 4% of the initial inoculum, and by 4 h it was I ± 0.lI% (Figure 4a ). The control cell number recoverable over 4 h was 78 ± 4-90 ± 9% of the initial inoculum.
Surviving treated and control cells were washed and cultured in fresh medium without D-Phe5SP. After I week the control cells had grown to 1706 ± 51-2530 ± 59% of the initial cell number. Cells pre-exposed to D-Phe5SP for I h showed similar growth to controls. However, cells which had survived 2. 3 and 4 h exposure had a significantly (P<0.01) reduced ability to grow. with cell number increases of 647 ± 20%, 224 ± 4% and 335 ± 7% respectively ( Figure  4b ). The same effects were found in two separate experiments, both carried out on the HC12 cell line. n D-PhefSP effect on colony forming efficiency (CFE) of cell lines and normal human bone marrow D-Phe5SP caused dose dependent inhibition of colony formation (P<0.01) in 3 3 SCLC CLs and 11 squamous lung carcinoma CL. while substance P had no effect (Table II) (Woll & Rozengurt. 1988b; Woll & Rozengurt. 1990) (Figure  1 ). In addition. we have demonstrated equivalent inhibition of DNA synthesis in fresh SCLC tumour cells from a previously untreated patient. a squamous lung carcinoma cell line. a squamous cervical carcinoma cell line. and two ovarian carcinoma cell lines (Table I) .
Previous studies have focused on the ability of the SP analogues to antagonise interaction of neuropeptide growth factors. particularly bombesin. with cell surface receptors (Woll & Rozengurt. 1988a : Woll & Rozengurt. 1988b : Takuwa et al.. 1990 . Squamous lung carcinoma cell line NCI-H226 lacks detectable bombesin receptors (Moody et al.. 1983) and appears to be slightly less sensitive to the analogue than the SCLC cell lines. However growth was undoubtedly inhibited (Table II) (Takuwa et al.. 1990) . This is in contrast with results in Swiss 3T3 cells. where the inhibitory effects of SP analogues can be reversed by excess gastrin releasing peptide (GRP) (Woll & Rozengurt. 1988b (Figure 4b ). This difference in reversibility may simply reflect the reported increased potency of D-Phe5SP over DAPTL-SP (Woll & Rozengurt. 1988b ). or they may be inhibiting growth through different mechanisms.
In general D-Phe'SP was less potent when tested against normal human skin fibroblasts ( Figure 3 ) and human bone marrow cells (Table II) In summary D-Phe5SP shows antitumour effects against several different tumour cell types. including SCLC. squamous lung carcinoma, ovarian and squamous cervical carcinoma. with less growth inhibition seen against normal human skin fibroblasts and bone marrow. There is substantial cell death after 2-4 h exposure to 100 jim D-Phe5SP. and surviving cells exhibit growth inhibition. These results suggest that D-Phe5SP merits further study as a potential novel antitumour agent. We are currently investigating the mechanism of action and in vivo activity.
